By binding to PD-1, activating antigen-specific T cells, and reversing the immune evasion of cancer, immunotherapy may be more effective in the early stages of G/GEJ cancers when the tumor is still present after the approach known as neoadjuvant therapy13. The gene discussed is PDCD1; the disease is cancer.